Skip to main content

Advertisement

Table 1 HER-2/neu amplification status by multiplex ligation-dependent probe amplification (MLPA) of 42 breast cancer patients in undissected sections and after manual and laser microdissection, in comparison with in situ hybridization and immunohistochemistry.

From: HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection

    MLPA   
Case number IHC ISH Undissected Manual MD Laser MD DCIS Tumor %
1 0 NA 1 1 1 Yes 30
2 0 NA 1 1 1   30
3 0 NA 1 1 1 Yes 10
4 2 NA 1 1 1   10
5 2 NA 1 1 1 Yes 70
6 2 NA 1 1 2 Yes 70
7 2 NA 1 1 1   50
8 2 NA 1 1 1   70
9 2 NA 1 1 1   70
10 2 NA 1 1 1   60
11 2 NA 1 1 1   30
12 2 NA 1 1 1   60
13 1 LA 2 2 2   70
14 2 A 2 3 3   80
15 2 A 2 2 3 Yes 80
16 3 A 2 2 3   80
17 2 LA 2 2 3   80
18 0 NA 2 1 1 Yes 90
19 0 NA 2 1 1   80
20 1 A 2 3 3   70
21 1 LA 2 3 2 Yes 50
22 1 NA 2 2 1 Yes 80
23 1 NA 2 1 1 Yes 10
24 1 NA 2 1 1 Yes 60
25 0 NA 3 1 1   60
26 0 NA 3 1 1   80
27 1 A 3 3 3   70
28 1 NA 3 3 3 Yes 30
29 3 A 3 3 3   50
30 1 A 3 3 3   80
31 2 A 3 3 3 Yes 70
32 3 A 3 3 3 Yes 80
33 3 A 3 3 3   20
34 3 A 3 3 3   70
35 3 A 3 3 3   80
36 3 A 3 3 3   70
37 3 A 3 3 3   30
38 3 A 3 3 3   70
39 3 A 3 3 3   60
40 2 A 3 3 3 Yes 40
41 3 A 3 3 3 Yes 20
42 3 A 3 3 3   10
  1. IHC = immunohistochemistry (Hercep test), ISH = in situ hybridization, NA = non-amplified, LA = low-level amplified, A = amplified, MD = microdissection, DCIS = ductal carcinoma in situ